63-PUB: Diabetes Control and Complications in South India—Three-Year Results of LANDMARC Trial
Glycemic control, therapy trends, and diabetes complications were evaluated in LANDMARC — a prospective observational 3-year (y) study (CTRI/2017/05/008452) of participants with T2D on ≥2 antihyperglycemic medications. This sub-analysis of 135 sites in South India (Bangalore, Chennai, Coimbatore, Hy...
Gespeichert in:
| Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2024-06, Vol.73 (Supplement_1), p.1 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | 1 |
| container_title | Diabetes (New York, N.Y.) |
| container_volume | 73 |
| creator | THACKER, HEMANT PRASANNA KUMAR, K.M. DAS, ASHOK K. RAMANATHAN, BALAMURUGAN ASIRVATHAM, ARTHUR K. SHUNMUGAVELU, MINAKSHISUNDARAM MRUTHYUNJAYA, MAHESH D. SELVAN, CHITRA SUNDARAM, VIVEK PHILIP, ELIZABETH MENON, SHALINI K. GADEKAR, ARVIND CHODANKAR, DEEPA |
| description | Glycemic control, therapy trends, and diabetes complications were evaluated in LANDMARC — a prospective observational 3-year (y) study (CTRI/2017/05/008452) of participants with T2D on ≥2 antihyperglycemic medications. This sub-analysis of 135 sites in South India (Bangalore, Chennai, Coimbatore, Hyderabad, Kerala, and Vijayawada) included 2354 participants (mean [SD] baseline [BL] age: 51.4 [9.2] y, T2D duration: 8.4 [5.5] y and A1C: 8.1% [1.6]). At BL, most were insulin-naïve (n=1665; 70.8%), mainly on OADs (n=1638; 69.6%). At 3 y, 1149 (57.8%) participants were on OADs only, while 806 (40.5%) were on insulin + OADs. Biguanides was the most prescribed drug class (BL: 2184/2353 [92.8%] and 3 y: 1853/1988 [93.2%]). Basal insulin usage increased from BL (n=335; 14.2%) to 3 y (n=465; 23.4%). A decrease in mean (SD) A1C (-0.6 [1.7] %), FPG (-18.0 [60.3] mg/dL), and PPG (-30.3 [81.5] mg/dL); and an increase in those with A1C |
| doi_str_mv | 10.2337/db24-63-PUB |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_3111276005</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3111276005</sourcerecordid><originalsourceid>FETCH-LOGICAL-c645-aa08753e2a0cdc7c9b87d33c74ffd42d120673137895538a774fda11f99c14373</originalsourceid><addsrcrecordid>eNotkMtOwzAQRS0EEqWw4gcssUQG25PECbuS8qhUHipBgpVxbUdNlcbBThbs-Ai-kC8hVdEsZqQ5ulc6CJ0yesEBxKVZ8ogkQJ5fr_fQiGWQEeDibR-NKGWcMJGJQ3QUwppSmgwzQh87-gpPK7W0nQ04d03nXY1VY4Z709aVVl3lmoCrBr-4vlvhWWMq9fv9U6y8teTdKo8XNvR1F7Ar8XzyOH2YLHJc-ErVx-igVHWwJ_97jIrbmyK_J_Onu1k-mROdRDFRiqYiBssV1UYLnS1TYQC0iMrSRNwwThMBDESaxTGkSgwPoxgrs0yzCASM0dkutvXus7ehk2vX-2ZolMAY4yKhNB6o8x2lvQvB21K2vtoo_yUZlVuDcmtQJiAHJ_AH36diQA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3111276005</pqid></control><display><type>article</type><title>63-PUB: Diabetes Control and Complications in South India—Three-Year Results of LANDMARC Trial</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>THACKER, HEMANT ; PRASANNA KUMAR, K.M. ; DAS, ASHOK K. ; RAMANATHAN, BALAMURUGAN ; ASIRVATHAM, ARTHUR K. ; SHUNMUGAVELU, MINAKSHISUNDARAM ; MRUTHYUNJAYA, MAHESH D. ; SELVAN, CHITRA ; SUNDARAM, VIVEK ; PHILIP, ELIZABETH ; MENON, SHALINI K. ; GADEKAR, ARVIND ; CHODANKAR, DEEPA</creator><creatorcontrib>THACKER, HEMANT ; PRASANNA KUMAR, K.M. ; DAS, ASHOK K. ; RAMANATHAN, BALAMURUGAN ; ASIRVATHAM, ARTHUR K. ; SHUNMUGAVELU, MINAKSHISUNDARAM ; MRUTHYUNJAYA, MAHESH D. ; SELVAN, CHITRA ; SUNDARAM, VIVEK ; PHILIP, ELIZABETH ; MENON, SHALINI K. ; GADEKAR, ARVIND ; CHODANKAR, DEEPA</creatorcontrib><description>Glycemic control, therapy trends, and diabetes complications were evaluated in LANDMARC — a prospective observational 3-year (y) study (CTRI/2017/05/008452) of participants with T2D on ≥2 antihyperglycemic medications. This sub-analysis of 135 sites in South India (Bangalore, Chennai, Coimbatore, Hyderabad, Kerala, and Vijayawada) included 2354 participants (mean [SD] baseline [BL] age: 51.4 [9.2] y, T2D duration: 8.4 [5.5] y and A1C: 8.1% [1.6]). At BL, most were insulin-naïve (n=1665; 70.8%), mainly on OADs (n=1638; 69.6%). At 3 y, 1149 (57.8%) participants were on OADs only, while 806 (40.5%) were on insulin + OADs. Biguanides was the most prescribed drug class (BL: 2184/2353 [92.8%] and 3 y: 1853/1988 [93.2%]). Basal insulin usage increased from BL (n=335; 14.2%) to 3 y (n=465; 23.4%). A decrease in mean (SD) A1C (-0.6 [1.7] %), FPG (-18.0 [60.3] mg/dL), and PPG (-30.3 [81.5] mg/dL); and an increase in those with A1C<7% (BL: 414 [24.5%]; 3 y: 440 [30.1%]), was noted. MI and neuropathy were the most common macro and microvascular complications, respectively (Table). The rate of microvascular complications (n, %) was highest in South India (519, 22.1%) vs. West (252, 18.8%), North (243, 14.4%) and East (107, 12.7%) at 3 y. Hypertension and dyslipidemia were the most common CV risk factors. There is need to further evaluate diabetes management strategies employed in South India to achieve optimal glycemic control.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db24-63-PUB</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Diabetes ; Diabetes mellitus ; Diabetic neuropathy ; Disease management ; Dyslipidemia ; Insulin ; Microvasculature ; Neuropathy ; Risk factors</subject><ispartof>Diabetes (New York, N.Y.), 2024-06, Vol.73 (Supplement_1), p.1</ispartof><rights>Copyright American Diabetes Association Jun 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>THACKER, HEMANT</creatorcontrib><creatorcontrib>PRASANNA KUMAR, K.M.</creatorcontrib><creatorcontrib>DAS, ASHOK K.</creatorcontrib><creatorcontrib>RAMANATHAN, BALAMURUGAN</creatorcontrib><creatorcontrib>ASIRVATHAM, ARTHUR K.</creatorcontrib><creatorcontrib>SHUNMUGAVELU, MINAKSHISUNDARAM</creatorcontrib><creatorcontrib>MRUTHYUNJAYA, MAHESH D.</creatorcontrib><creatorcontrib>SELVAN, CHITRA</creatorcontrib><creatorcontrib>SUNDARAM, VIVEK</creatorcontrib><creatorcontrib>PHILIP, ELIZABETH</creatorcontrib><creatorcontrib>MENON, SHALINI K.</creatorcontrib><creatorcontrib>GADEKAR, ARVIND</creatorcontrib><creatorcontrib>CHODANKAR, DEEPA</creatorcontrib><title>63-PUB: Diabetes Control and Complications in South India—Three-Year Results of LANDMARC Trial</title><title>Diabetes (New York, N.Y.)</title><description>Glycemic control, therapy trends, and diabetes complications were evaluated in LANDMARC — a prospective observational 3-year (y) study (CTRI/2017/05/008452) of participants with T2D on ≥2 antihyperglycemic medications. This sub-analysis of 135 sites in South India (Bangalore, Chennai, Coimbatore, Hyderabad, Kerala, and Vijayawada) included 2354 participants (mean [SD] baseline [BL] age: 51.4 [9.2] y, T2D duration: 8.4 [5.5] y and A1C: 8.1% [1.6]). At BL, most were insulin-naïve (n=1665; 70.8%), mainly on OADs (n=1638; 69.6%). At 3 y, 1149 (57.8%) participants were on OADs only, while 806 (40.5%) were on insulin + OADs. Biguanides was the most prescribed drug class (BL: 2184/2353 [92.8%] and 3 y: 1853/1988 [93.2%]). Basal insulin usage increased from BL (n=335; 14.2%) to 3 y (n=465; 23.4%). A decrease in mean (SD) A1C (-0.6 [1.7] %), FPG (-18.0 [60.3] mg/dL), and PPG (-30.3 [81.5] mg/dL); and an increase in those with A1C<7% (BL: 414 [24.5%]; 3 y: 440 [30.1%]), was noted. MI and neuropathy were the most common macro and microvascular complications, respectively (Table). The rate of microvascular complications (n, %) was highest in South India (519, 22.1%) vs. West (252, 18.8%), North (243, 14.4%) and East (107, 12.7%) at 3 y. Hypertension and dyslipidemia were the most common CV risk factors. There is need to further evaluate diabetes management strategies employed in South India to achieve optimal glycemic control.</description><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetic neuropathy</subject><subject>Disease management</subject><subject>Dyslipidemia</subject><subject>Insulin</subject><subject>Microvasculature</subject><subject>Neuropathy</subject><subject>Risk factors</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNotkMtOwzAQRS0EEqWw4gcssUQG25PECbuS8qhUHipBgpVxbUdNlcbBThbs-Ai-kC8hVdEsZqQ5ulc6CJ0yesEBxKVZ8ogkQJ5fr_fQiGWQEeDibR-NKGWcMJGJQ3QUwppSmgwzQh87-gpPK7W0nQ04d03nXY1VY4Z709aVVl3lmoCrBr-4vlvhWWMq9fv9U6y8teTdKo8XNvR1F7Ar8XzyOH2YLHJc-ErVx-igVHWwJ_97jIrbmyK_J_Onu1k-mROdRDFRiqYiBssV1UYLnS1TYQC0iMrSRNwwThMBDESaxTGkSgwPoxgrs0yzCASM0dkutvXus7ehk2vX-2ZolMAY4yKhNB6o8x2lvQvB21K2vtoo_yUZlVuDcmtQJiAHJ_AH36diQA</recordid><startdate>20240614</startdate><enddate>20240614</enddate><creator>THACKER, HEMANT</creator><creator>PRASANNA KUMAR, K.M.</creator><creator>DAS, ASHOK K.</creator><creator>RAMANATHAN, BALAMURUGAN</creator><creator>ASIRVATHAM, ARTHUR K.</creator><creator>SHUNMUGAVELU, MINAKSHISUNDARAM</creator><creator>MRUTHYUNJAYA, MAHESH D.</creator><creator>SELVAN, CHITRA</creator><creator>SUNDARAM, VIVEK</creator><creator>PHILIP, ELIZABETH</creator><creator>MENON, SHALINI K.</creator><creator>GADEKAR, ARVIND</creator><creator>CHODANKAR, DEEPA</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20240614</creationdate><title>63-PUB: Diabetes Control and Complications in South India—Three-Year Results of LANDMARC Trial</title><author>THACKER, HEMANT ; PRASANNA KUMAR, K.M. ; DAS, ASHOK K. ; RAMANATHAN, BALAMURUGAN ; ASIRVATHAM, ARTHUR K. ; SHUNMUGAVELU, MINAKSHISUNDARAM ; MRUTHYUNJAYA, MAHESH D. ; SELVAN, CHITRA ; SUNDARAM, VIVEK ; PHILIP, ELIZABETH ; MENON, SHALINI K. ; GADEKAR, ARVIND ; CHODANKAR, DEEPA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c645-aa08753e2a0cdc7c9b87d33c74ffd42d120673137895538a774fda11f99c14373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetic neuropathy</topic><topic>Disease management</topic><topic>Dyslipidemia</topic><topic>Insulin</topic><topic>Microvasculature</topic><topic>Neuropathy</topic><topic>Risk factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>THACKER, HEMANT</creatorcontrib><creatorcontrib>PRASANNA KUMAR, K.M.</creatorcontrib><creatorcontrib>DAS, ASHOK K.</creatorcontrib><creatorcontrib>RAMANATHAN, BALAMURUGAN</creatorcontrib><creatorcontrib>ASIRVATHAM, ARTHUR K.</creatorcontrib><creatorcontrib>SHUNMUGAVELU, MINAKSHISUNDARAM</creatorcontrib><creatorcontrib>MRUTHYUNJAYA, MAHESH D.</creatorcontrib><creatorcontrib>SELVAN, CHITRA</creatorcontrib><creatorcontrib>SUNDARAM, VIVEK</creatorcontrib><creatorcontrib>PHILIP, ELIZABETH</creatorcontrib><creatorcontrib>MENON, SHALINI K.</creatorcontrib><creatorcontrib>GADEKAR, ARVIND</creatorcontrib><creatorcontrib>CHODANKAR, DEEPA</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>THACKER, HEMANT</au><au>PRASANNA KUMAR, K.M.</au><au>DAS, ASHOK K.</au><au>RAMANATHAN, BALAMURUGAN</au><au>ASIRVATHAM, ARTHUR K.</au><au>SHUNMUGAVELU, MINAKSHISUNDARAM</au><au>MRUTHYUNJAYA, MAHESH D.</au><au>SELVAN, CHITRA</au><au>SUNDARAM, VIVEK</au><au>PHILIP, ELIZABETH</au><au>MENON, SHALINI K.</au><au>GADEKAR, ARVIND</au><au>CHODANKAR, DEEPA</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>63-PUB: Diabetes Control and Complications in South India—Three-Year Results of LANDMARC Trial</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2024-06-14</date><risdate>2024</risdate><volume>73</volume><issue>Supplement_1</issue><spage>1</spage><pages>1-</pages><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Glycemic control, therapy trends, and diabetes complications were evaluated in LANDMARC — a prospective observational 3-year (y) study (CTRI/2017/05/008452) of participants with T2D on ≥2 antihyperglycemic medications. This sub-analysis of 135 sites in South India (Bangalore, Chennai, Coimbatore, Hyderabad, Kerala, and Vijayawada) included 2354 participants (mean [SD] baseline [BL] age: 51.4 [9.2] y, T2D duration: 8.4 [5.5] y and A1C: 8.1% [1.6]). At BL, most were insulin-naïve (n=1665; 70.8%), mainly on OADs (n=1638; 69.6%). At 3 y, 1149 (57.8%) participants were on OADs only, while 806 (40.5%) were on insulin + OADs. Biguanides was the most prescribed drug class (BL: 2184/2353 [92.8%] and 3 y: 1853/1988 [93.2%]). Basal insulin usage increased from BL (n=335; 14.2%) to 3 y (n=465; 23.4%). A decrease in mean (SD) A1C (-0.6 [1.7] %), FPG (-18.0 [60.3] mg/dL), and PPG (-30.3 [81.5] mg/dL); and an increase in those with A1C<7% (BL: 414 [24.5%]; 3 y: 440 [30.1%]), was noted. MI and neuropathy were the most common macro and microvascular complications, respectively (Table). The rate of microvascular complications (n, %) was highest in South India (519, 22.1%) vs. West (252, 18.8%), North (243, 14.4%) and East (107, 12.7%) at 3 y. Hypertension and dyslipidemia were the most common CV risk factors. There is need to further evaluate diabetes management strategies employed in South India to achieve optimal glycemic control.</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db24-63-PUB</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1797 |
| ispartof | Diabetes (New York, N.Y.), 2024-06, Vol.73 (Supplement_1), p.1 |
| issn | 0012-1797 1939-327X |
| language | eng |
| recordid | cdi_proquest_journals_3111276005 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Diabetes Diabetes mellitus Diabetic neuropathy Disease management Dyslipidemia Insulin Microvasculature Neuropathy Risk factors |
| title | 63-PUB: Diabetes Control and Complications in South India—Three-Year Results of LANDMARC Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T00%3A53%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=63-PUB:%20Diabetes%20Control%20and%20Complications%20in%20South%20India%E2%80%94Three-Year%20Results%20of%20LANDMARC%20Trial&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=THACKER,%20HEMANT&rft.date=2024-06-14&rft.volume=73&rft.issue=Supplement_1&rft.spage=1&rft.pages=1-&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db24-63-PUB&rft_dat=%3Cproquest_cross%3E3111276005%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3111276005&rft_id=info:pmid/&rfr_iscdi=true |